Aspira Women's Health Reports Flat Q3 Revenue and Higher Gross Margin
I'm PortAI, I can summarize articles.
Aspira Women's Health reported Q3 2025 product revenues of $2.3 million, flat compared to Q3 2024. The average unit price per test rose by 7% year-over-year, and gross profit margin improved by 5.7%. The company is advancing R&D, focusing on its ENDOinform™ program and expanding OvaSuite™ technology in major IDNs for ovarian cancer risk assessment. Aspira aims to strengthen ties with large healthcare systems and IDNs.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments